ArticleAmerican journal of translational research2026
Downregulation of miR-130b-3p is associated with the progression of type 2 diabetic nephropathy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the association between miR-130b-3p and the progression of type 2 diabetic nephropathy (T2DN) and the underlying mechanisms.
methodsA total of 279 patients with T2DN were enrolled and divided into the normal albuminuria (NAU) group (n=117), microalbuminuria (MIAU) group (n=98), and the macroalbuminuria (MAAU) group (n=64). Additionally, 80 healthy subjects were selected as the control group. The expression of miR-130b-3p was measured in each group, and the clinical biochemical parameters were recorded. A diabetic nephropathy (DN) rat model was established to further analyze the relationship between miR-130b-3p expression and the Bcl-2/Bax pathway.
resultsThe relative expression level of miR-130b-3p was significantly decreased in patients with type 2 diabetic nephropathy (T2DN). Moreover, its expression in patients of the MAAU group was notably lower than that in patients of the MIAU group. miR-130b-3p in T2DN patients was substantially negatively correlated with the course of disease, HbA1c, HOMA-IR, triglycerides, eGFR, TGF-β1 and TNF-α. Receiver operating characteristic (ROC) curve analysis demonstrated the diagnostic value of miR-130-3p for DN, with an area under the curve (AUC) of 0.854. Compared with the control group, the expression of miR-130b-3p and Bcl-2 in renal tissues of rats in the DN model group was significantly decreased, while the expression of Bax and caspase-3 was significantly increased. Additionally, the number of apoptotic cells in the renal cortex of rats in the DN model group was significantly higher than that in the control group.
conclusionDownregulation of miR-130b-3p in T2DN patients may reflect early renal injury in DN. Its underlying mechanism may involve the induction of apoptosis through the mitochondrial pathway activation, mediated by Bcl-2/Bax imbalance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.